Trial Search Results

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in detecting lactate and bicarbonate in participants with central nervous system tumors. Hyperpolarized carbon C 13 pyruvate magnetic resonance imaging may be used to measure the metabolic state of malignant brain tumors.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Daniel M. Spielman

Stanford Investigator(s):

Intervention(s):

  • Other: Gadolinium
  • Drug: Hyperpolarized Carbon C 13 Pyruvate
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Magnetic Resonance Spectroscopic Imaging

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Patients with a known diagnosis of central nervous system (CNS) malignancy, including
   metastases, with known enhancement on magnetic resonance (MR) who are otherwise
   eligible to undergo MRI

   - Glomerular filtration rate (GFR) > 30 ml/min

   - No allergy to gadolinium

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Refusal to have an IV placed for injection

   - Acute major illness (e.g., unstable angina, etc.) or other condition that makes
   participation unsafe, per the investigator?s judgement

   - Total bilirubin > 1.5 x upper limit of normal (ULN)

   - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN

   - Gamma-glutamyltransferase (GGT) > 2.5 x ULN

   - Pregnant or breast-feeding

   - Cardiovascular risk, including:

      - Poorly controlled hypertension, defined as either systolic > 170 or diastolic >
      110

      - Congestive heart failure

      - Myocardial infarction within the past year

      - QT prolongation, defined as pretreatment corrected QT interval (QTc) > 440 msec
      in males or > 460 msec in females

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lewis Naya
650-725-0739
Recruiting